This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagai, M. Articles by Weber, G. Search for Related Content PubMed PubMed Citation Articles by Nagai, M. Articles by Weber, G.

Proliferation-linked Regulation of Type II IMP Dehydrogenase Gene in Human Normal Lymphocytes and HL-60 Leukemic Cells¹

Laboratory for Experimental Oncology [M. N., Y. N., G. W.] and Walther Oncology Center [M. N.], Indiana University School of Medicine, Indianapolis, Indiana 46202-5200

Human IMP dehydrogenase (IMPDH; EC 1.1.1.205) was recently found to consist of two molecular species (types I and II) with high expression of type II isozyme in leukemic cells. Here we report that the low level of type II mRNA in normal lymphocytes was up-regulated by phytohemagglutinin stimulation (3.2-fold) and Epstein-Barr viral transformation (5.7-fold). The type II mRNA expression in quiescent HL-60 cells was also elevated 2.8-fold by serum stimulation. Conversely the enhanced level of type II IMPDH mRNA in HL-60 cells was down-regulated to less than 5% along with differentiation induced by retinoic acid (1 µM), phorbol-12-myristate-13-acetate (33 nM), or dimethyl sulfoxide (1.25%) independent of end-stage phenotype. By contrast, type I IMPDH mRNA was expressed constitutively in the various states of proliferation and differentiation. The type II IMPDH stringently linked with cell proliferation should be a crucial target for antileukemic and immunosuppressive chemotherapy.

¹ This work was supported in part by USPHS Outstanding Investigator Grant CA-42510 and American Cancer Society Grant RD-288 awarded to G. W., and by American Cancer Society Institutional Grant IN-161-D awarded to M. N.

² To whom requests for reprints should be addressed.

Received 8/16/91. Accepted 11/ 1/91.

This article has been cited by other articles:

				S. KOKENY, J. PAPP, G. WEBER, T. VASZKO, P. CARMONA-SAEZ, and E. OLAH Ribavirin Acts via Multiple Pathways in Inhibition of Leukemic Cell Proliferation Anticancer Res, June 1, 2009; 29(6): 1971 - 1980. [Abstract] [Full Text] [PDF]

				L. C.S. Tam, A.-S. Kiang, A. Kennan, P. F. Kenna, N. Chadderton, M. Ader, A. Palfi, A. Aherne, C. Ayuso, M. Campbell, et al. Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10) Hum. Mol. Genet., July 15, 2008; 17(14): 2084 - 2100. [Abstract] [Full Text] [PDF]

				X.-X. Sun, M.-S. Dai, and H. Lu Mycophenolic Acid Activation of p53 Requires Ribosomal Proteins L5 and L11 J. Biol. Chem., May 2, 2008; 283(18): 12387 - 12392. [Abstract] [Full Text] [PDF]

				A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco Mycophenolate mofetil and systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 44 - 54. [Abstract] [PDF]

				Y. Ji, J. Gu, A. M. Makhov, J. D. Griffith, and B. S. Mitchell Regulation of the Interaction of Inosine Monophosphate Dehydrogenase with Mycophenolic Acid by GTP J. Biol. Chem., January 6, 2006; 281(1): 206 - 212. [Abstract] [Full Text] [PDF]

				Y.-M. Ku, M. McCartan, and D. Collier Clinical Pharmacokinetic and Pharmacodynamic Monitoring for Mycophenolate Mofetil Journal of Pharmacy Practice, December 1, 2005; 18(6): 422 - 431. [Abstract] [PDF]

				S. Ignoul and J. Eggermont CBS domains: structure, function, and pathology in human proteins Am J Physiol Cell Physiol, December 1, 2005; 289(6): C1369 - C1378. [Abstract] [Full Text] [PDF]

				L. Rambhatla, S. Ram-Mohan, J. J. Cheng, and J. L. Sherley Immortal DNA Strand Cosegregation Requires p53/IMPDH-Dependent Asymmetric Self-renewal Associated with Adult Stem Cells Cancer Res., April 15, 2005; 65(8): 3155 - 3161. [Abstract] [Full Text] [PDF]

				J. J. Gu, L. Santiago, and B. S. Mitchell Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl Blood, April 15, 2005; 105(8): 3270 - 3277. [Abstract] [Full Text] [PDF]

				M. Escobar-Henriques, M. A. Collart, and B. Daignan-Fornier Transcription Initiation of the Yeast IMD2 Gene Is Abolished in Response to Nutrient Limitation through a Sequence in Its Coding Region Mol. Cell. Biol., September 1, 2003; 23(17): 6279 - 6290. [Abstract] [Full Text] [PDF]

				J. W. Hyle, R. J. Shaw, and D. Reines Functional Distinctions between IMP Dehydrogenase Genes in Providing Mycophenolate Resistance and Guanine Prototrophy to Yeast J. Biol. Chem., August 1, 2003; 278(31): 28470 - 28478. [Abstract] [Full Text] [PDF]

				J. J. Gu, K. Gathy, L. Santiago, E. Chen, M. Huang, L. M. Graves, and B. S. Mitchell Induction of apoptosis in IL-3-dependent hematopoietic cell lines by guanine nucleotide depletion Blood, June 15, 2003; 101(12): 4958 - 4965. [Abstract] [Full Text] [PDF]

				B. J. Barnes, R. A. Izydore, A. E. Eakin, and I. H. Hall Induction of Tmolt4 Leukemia Cell Death by 3,3-Disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: Specificity for Type II Inosine 5'-Monophosphate Dehydrogenase J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 790 - 796. [Abstract] [Full Text] [PDF]

				T. D. Colby, K. Vanderveen, M. D. Strickler, G. D. Markham, and B. M. Goldstein Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design PNAS, March 30, 1999; 96(7): 3531 - 3536. [Abstract] [Full Text] [PDF]

				Y. Liu, S. A. Bohn, and J. L. Sherley Inosine-5'-Monophosphate Dehydrogenase Is a Rate-determining Factor for p53-dependent Growth Regulation Mol. Biol. Cell, January 1, 1998; 9(1): 15 - 28. [Abstract] [Full Text]

				A. Griesmacher, G. Weigel, G. Seebacher, and M. M. Muller IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide Clin. Chem., December 1, 1997; 43(12): 2312 - 2317. [Abstract] [Full Text] [PDF]

				A. G. Zimmermann, K. L. Wright, J. P.-Y. Ting, and B. S. Mitchell Regulation of Inosine-5'-monophosphate Dehydrogenase Type II Gene Expression in Human T Cells. ROLE FOR A NOVEL 5' PALINDROMIC OCTAMER SEQUENCE J. Biol. Chem., September 5, 1997; 272(36): 22913 - 22923. [Abstract] [Full Text] [PDF]

				J. J. Gu, J. Spychala, and B. S. Mitchell Regulation of the Human Inosine Monophosphate Dehydrogenase Type I Gene. UTILIZATION OF ALTERNATIVE PROMOTERS J. Biol. Chem., February 14, 1997; 272(7): 4458 - 4466. [Abstract] [Full Text] [PDF]

				T. Farazi, J. Leichman, T. Harris, M. Cahoon, and L. Hedstrom Isolation and Characterization of Mycophenolic Acid-resistant Mutants of Inosine-5'-monophosphate Dehydrogenase J. Biol. Chem., January 10, 1997; 272(2): 961 - 965. [Abstract] [Full Text] [PDF]

				E. Nimmesgern, T. Fox, M. A. Fleming, and J. A. Thomson Conformational Changes and Stabilization of Inosine 5'-Monophosphate Dehydrogenase Associated with Ligand Binding and Inhibition by Mycophenolic Acid J. Biol. Chem., August 9, 1996; 271(32): 19421 - 19427. [Abstract] [Full Text] [PDF]

				A. G. Zimmermann, J. Spychala, and B. S. Mitchell Characterization of the Human Inosine-5`-monophosphate Dehydrogenase Type II Gene J. Biol. Chem., March 24, 1995; 270(12): 6808 - 6814. [Abstract] [Full Text] [PDF]

				M. Escobar-Henriques and B. Daignan-Fornier Transcriptional Regulation of the Yeast GMP Synthesis Pathway by Its End Products J. Biol. Chem., January 5, 2001; 276(2): 1523 - 1530. [Abstract] [Full Text] [PDF]